In a phase II clinical trial (N = 55), defactinib, a selective oral inhibitor of focal adhesion kinase (FAK), demonstrated modest clinical activity in heavily pre-treated KRAS-mutated NSCLC patients [70]. Here, PTK2 is linked to non-small cell lung carcinoma.